Compound ID | 315
ME1036 (CP5609)
Class: Beta-lactam
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against Haemophilus infections, and methicillin-resistant Staphylococcus aureus |
| Description: | Semisynthetic compound containing 7-acylated imidazo[5,1-b]thiazole-2-yl group |
| Institute where first reported: | Meiji Seika Kaisha (Meiji Seika Pharma., Japan); licensed to Cerexa (Actavis, Ireland) |
| Year first mentioned: | 2002 |
| Development status: | Experimental |
| Reason dropped: | Meiji Seika Kaisha have discontinued research of this but rights were licensed to Cerexa who was later taken over by Forest Laboratories, LLC. In 2006 and subsequently in 2014 by Actavis. It is unclear whether this is still active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/substance/134222972 |
| Citation: | https://doi.org/10.1128/aac.48.8.2831-2837.2004 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.